Drug Profile


Alternative Names: ACUD1

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Emory University
  • Developer Accuitis; Emory University; Mercer University
  • Class
  • Mechanism of Action Interleukin 6 inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis; Rosacea

Most Recent Events

  • 23 Nov 2015 Preclinical trials in Rosacea in USA (Topical)
  • 23 Nov 2015 Accuitis secures a Phase IIIA loan from Georgia Research Alliance to finance development of ACU-D1 for Rosacea
  • 23 Nov 2015 Accuitis plans a phase I/II trial for Rosacea in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top